LifeMD 

LifeMD, Inc. is a telehealth company, which engages in offering portfolio of direct-to-patient products and services. It combines virtual medical treatment with prescription medications and over-the-counter products. The firm's network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the United States. The firm's brands include Shapiro, Rex, and Nava. The company was founded in 1987 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AGF Management reports stable performance and growth opportunities in Q1 2023

AGF Management delivered stable performance in Q1 2023 with positive net sales and a dividend increase.
While facing challenges in certain business segments, AGF's strong cash position and investment portfolio provide a solid foundation.
Opportunities lie in capital allocation strategies, growth initiatives, and enhancing performance in key business areas.
Overall, AGF's focus on shareholder returns and strategic investments positions the company for future growth and success.

LifeMD surpasses Q1 expectations, eyes growth amid challenges

LifeMD's Q1 2023 performance exceeded expectations, driven by strong revenue and EBITDA results.
The company's strategic initiatives, including debt financing and AI integration, position it for growth.
Challenges lie in maintaining growth momentum, managing costs, and optimizing EBITDA margins.
Opportunities in partnerships, telehealth, and patient value enhancement offer avenues for future growth.

LifeMD reports strong Q2 performance and raises revenue guidance

LifeMD's Q2 performance reflects operational strength, revenue growth, and strategic initiatives driving positive results and financial stability.
While facing challenges in adjusted EBITDA guidance due to investments, the company maintains a strong position with record revenues and subscriber growth.
Opportunities for growth and expansion exist through the weight management program, partnerships, and focus on existing health care businesses.

LifeMD reports record Q3 revenue and profitability, eyes growth opportunities

LifeMD's Q3 results reflect a successful quarter marked by strong revenue, profitability, and subscriber growth. The company's focus on strategic initiatives and positive outlook for 2024 indicate a promising future with plans to accelerate momentum and deliver impressive results.

LifeMD reports record 2023 performance, eyes growth in weight management

LifeMD's strong performance in 2023 sets the stage for continued growth and profitability. The company's strategic focus on diversification, market expansion, and cost management positions it well for future success. Challenges in subscriber numbers and commercial partnerships require attention, but overall, LifeMD is on a positive trajectory.

LifeMD excels in Q2 with telehealth growth, WorkSimpli rebounds

LifeMD demonstrated robust performance in Q2 2024, driven by the success of its core telehealth business and strategic initiatives.
While facing challenges, WorkSimpli is making progress towards regaining peak profitability by addressing competitive and executional issues.
Opportunities lie in expanding service offerings, enhancing collaborations, and leveraging upcoming launches to drive growth and profitability for LifeMD.
Strategic focus on innovation, efficiency, and market differentiation positions LifeMD well for sustained success and revenue growth in the future.

LifeMD reports robust Q3 results, eyes Medicare expansion for growth

LifeMD's Q3 performance reflects strong revenue growth, operational improvements, and strategic expansion initiatives.
The company's focus on telehealth, men's health, and work simplification businesses is driving positive results.
While facing challenges in scaling operations and market competition, LifeMD is well-positioned for continued growth.
Opportunities in Medicare expansion, program enhancements, and market partnerships offer avenues for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

LifeMD reported impressive revenue growth, with a 60% increase to $44.9 million, driven by a 90% increase in telehealth revenues. Weight management subscribers more than doubled sequentially, resulting greater than 100% revenue growth quarter over quarter from this segment. Management raised its 2024 revenue forecast to at least $200 million, indicating strong growth potential and the likelihood of analyst upward revisions.

LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program

Hims & Hers Health

Eli Lilly

Novo Nordisk

Teladoc

Weightwatchers International Inc.

WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Sequence Inc. to enter into the GLP-1 clinical weight loss space, gaining the ability to prescribe medications like Novo Nordisk A/V NYSE: NVO owned Ozempic and Wegovy and Eli Lilly& Co. NYSE: LLY GLP-1 agonists like Mounjaro and Zepbound.

Can WeightWatchers Regain Its Mojo after Oprah Steps Down?

LifeMD, Inc. (NASDAQ:LFMD ) Q4 2023 Earnings Conference Call March 11, 2024 4:30 PM ET Company Participants Justin Schreiber - Chairman and CEO Marc Benathen - CFO Conference Call Participants David Larsen - BTIG William Wood - B. Riley Alex Fuhrman - Craig-Hallum Ilya Zubkov - Freedom Broker Yi Chen - H.C.

LifeMD, Inc. (LFMD) Q4 2023 Earnings Call Transcript

LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to earnings of $0.02 per share a year ago.

LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates

Fourth quarter revenue increased 60% year-over-year to $44.9 million with Telehealth revenues increasing 90% versus the year-ago period. Adjusted EPS of $0.15 per share compared with $0.02 in the year-ago period.

LifeMD Reports Fourth Quarter 2023 Results

NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced its participation in the 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, being held February 13-14, 2024 at the Cliff Lodge in Snowbird, Utah. Management will hold one-on-one meetings throughout the conference.

LifeMD to Participate in the 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

LifeMD, Inc.'s newly issued 2024 guidance indicates an impressive 38% CAGR, positioning it as an attractive investment opportunity. With a valuation priced at less than 11x forward EBITDA, LifeMD stock is considered advantageous, although investor skepticism persists regarding the sustainability of such growth rates in a competitive market. Despite concerns about the program's long-term sustainability, I believe the stock offers a favorable risk-reward scenario.

LifeMD's 2024: Striking A Balance Between Rapid Expansion And Sustainability

NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced its participation in the Maxim Group 2024 Healthcare IT Virtual Conference, being held January 24-25, 2024. Management will participate in a virtual fireside chat on Wednesday, January 24th at 10:00 a.m. Eastern time and will also hold one-on-one meetings throughout the conference. Investors can register for the conference here .

LifeMD to Participate in the Maxim Group 2024 Healthcare IT Virtual Conference

LifeMD expects a 38% increase in revenues for 2024, driven by its new telehealth operation for GLP-1 obesity drugs. Despite this, the stock is down significantly due to concerns over Eli Lilly direct marketing its GLP-1 obesity drugs. These fears are overblown. LifeMD's other operations are growing quickly and it is close to achieving breakeven earnings.

LifeMD: A GLP-1 Play With A Kicker

ALX Onconology Holdings Inc

Avino Silver & Gold Mines

Structure Therapeutics Inc

PetIQ

Skyward Specialty Insurance Group Inc

As we head into 2024, it's common for investors to look back on 2023. Much of this year had investors in a defensive posture.

7 Small-Cap Stocks That Wall Street Loves for Good Reason

Medifast

LifeMD Inc. NASDAQ: LFMD is a direct-to-consumer (DTC) comprehensive virtual healthcare platform. The company offers per-visit and membership plan pricing with no health insurance required.

LifeMD expands telehealth GLP-1weight-loss service with Medifast

Medifast partners with LifeMD to offer virtual weight management program with access to GLP-1 drugs. Medifast invests $20 million in LifeMD, with $10 million represented by common stock purchase. Survey shows over 40% of people with BMI greater than 27 are interested in prescription weight loss medication.

LifeMD: Medifast Partnership Further Validates Weight Management Program

The companies are teaming up to offer a ‘transformative weight management solution.'

LifeMD Stock Pops on Medifast Agreement. It's All About Weight-Loss Drugs.

LifeMD Inc.'s stock LFMD, +1.76% soared 9% early Wednesday, after the virtual primary care provider said it's teaming up with Medifast Inc. MED, +1.03%, a wellness company known for its habit-based and coach-guided lifestyle service Optavia, to create a clinically supported weight management program that will include the new class of weight-loss drugs called GLP-1. The drugs developed by Eli Lilly & Co. LLY, +0.12% and Denmark's Novo Nordisk NVO, -0.46% NOVO.B, +1.18% are named after a gut hormone that they mimic to control blood sugar have become highly popular and have even suffered shortages in the past year.

LifeMD's stock soars 9.5% on news company is teaming up with Medifast to create weight-management program that includes GLP-1 drugs

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today launched the first phase of its business transformation, as part of its commitment to providing comprehensive health and wellness solutions to customers across the United States. The company will expand into the medically supported weight loss market through a collaboration with LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual.

Medifast Initiates Business Transformation by Entering the Medically Supported Weight Loss Market through Collaboration with LifeMD, a Virtual Primary Care Provider, and Adjusting its Capital Allocation Policy

Collaboration will integrate LifeMD's telehealth platform and GLP-1 offering for medically qualified patients with OPTA VIA Coach-guided, healthy lifestyle solution

LifeMD and Medifast Partner to Offer Transformative Weight Management Solution

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. ™ (Nasdaq: LFMD), a leading provider of virtual primary care, today announced its participation in the RWJBarnabas Health Telehealth Symposium on Thursday, December 14 from 10:00 a.m. – 1:00 p.m. EST. The Symposium, which LifeMD is also sponsoring, will feature experts from RWJBarnabas Health and LifeMD discussing the increasingly important and complex role of telehealth in delivering quality and timely patient care.

LifeMD Executives to Participate in RWJBarnabas Health's Telehealth Symposium

LifeMD is recording strong growth figures on the back of WorkSimpli, its SaaS offering. The company currently sports an 87.62% gross profit margin and generated positive operating cash flow for its most recent quarter. Gross profit margins will see strength through 2024 as market sentiment toward growth stocks recovers to set the backdrop for continued outperformance.

LifeMD: My Tech Pick For 2024 And Its 12% Yielding Preferreds

LifeMD's weight management program has attracted over 16K subscribers in two quarters, producing $24M in annual recurring revenue run rate already, and this is only the beginning. Goldman Sachs argues that GLP-1 drugs are going to 16-fold by 2030 and LifeMD is a prime way to play this megatrend. There are multiple additional catalysts lined up to keep the weight management growth going, if not accelerating.

LifeMD Is The Stock To Play The Mega GLP-1 Drug Trend

LifeMD, Inc. (NASDAQ:LFMD ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Justin Schreiber - Chairman & Chief Executive Officer Marc Benathen - Chief Financial Officer Conference Call Participants Sarah James - Cantor Fitzgerald Yi Chen - H.C. Wainwright Brandon Carney - B.

LifeMD, Inc. (LFMD) Q3 2023 Earnings Call Transcript

Revenue increased 23% year-over-year to $38.6 million with both telehealth and WorkSimpli achieving record revenues. Adjusted EPS of $0.08 per share compared with a loss of $0.03 in the year-ago period.

LifeMD Reports Third Quarter 2023 Results; Record Revenue and Adjusted EBITDA

NEW YORK, NY, November 1, 2023 – LifeMD, Inc. is the current YTD leader in the PRISM Emerging Healthcare Index. The company has seen a ~226% increase this year and is trading at approximately $6 per share.

PRISM MARKETVIEW'S EMERGING HEALTHCARE INDEX HIGHLIGHTS LIFEMD, INC. AS ITS LARGEST YTD GAINER, UP ~226%

LifeMD, Inc.'s share price is soaring, once again. The company's focus on GLP-1 medications integration and primary care services exemplifies its commitment to comprehensive patient care. Its consistent increase in its share count could potentially dilute its progress.

LifeMD's Revival: The Phoenix Of The Health Industry

Joint Research Study Proved Particle's Platform Can Help Providers Contextualize and Comprehend Patient Data to Improve Care and Identify Those Eligible for GLP-1 Treatment Joint Research Study Proved Particle's Platform Can Help Providers Contextualize and Comprehend Patient Data to Improve Care and Identify Those Eligible for GLP-1 Treatment

Particle Health and LifeMD Demonstrate the Potential of Using Comprehensive Electronic Health Record Data to Triage Patients for GLP-1 Weight Management Therapy

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today launched a partnership with ASCEND Therapeutics US, LLC, a subsidiary of Besins Healthcare and a specialty pharmaceutical company concentrating on women's health, to provide integrated telehealth services to improve access to EstroGel® 0.06% (estradiol gel). LifeMD's telehealth services are now accessible on ASCEND Therapeutics' brand website, www.estrogel.com, allowing patients to connect with a LifeMD affiliated provider.

News for LifeMD Stock (LFMD)